Home » Stocks » CYAD

Celyad S.A. (CYAD)

Stock Price: $7.72 USD -0.15 (-1.91%)
Updated Feb 25, 2021 4:00 PM EST - Market closed
Market Cap 111.70M
Revenue (ttm) 6,742
Net Income (ttm) -32.17M
Shares Out 12.52M
EPS (ttm) -7.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $7.72
Previous Close $7.87
Change ($) -0.15
Change (%) -1.91%
Day's Open 7.86
Day's Range 7.63 - 7.87
Day's Volume 12,153
52-Week Range 4.10 - 13.01

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 3 weeks ago

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of ...

GlobeNewsWire - 3 weeks ago

MONT-SAINT-GUIBERT, Belgium, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of ...

GlobeNewsWire - 1 month ago

MONT-SAINT-GUIBERT, Belgium, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of ...

Benzinga - 1 month ago

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-base...

Other stocks mentioned: ACRS, GRTS, MRUS, NERV, TENX
GlobeNewsWire - 1 month ago

MONT-SAINT-GUIBERT, Belgium, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of ...

Seeking Alpha - 1 month ago

Celyad Oncology's technology, although still under development, has exciting possibilities, including the simplification of design and development of future therapy candidates, which could mak...

GlobeNewsWire - 1 month ago

MONT-SAINT-GUIBERT, Belgium, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of ...

GlobeNewsWire - 1 month ago

MONT-SAINT-GUIBERT, Belgium, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and...

GlobeNewsWire - 1 month ago

MONT-SAINT-GUIBERT, Belgium, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of ...

Business Wire - 1 month ago

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company f...

GlobeNewsWire - 2 months ago

MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of ...

Business Wire - 2 months ago

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company f...

GlobeNewsWire - 2 months ago

MONT-SAINT-GUIBERT, Belgium, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of ...

GlobeNewsWire - 2 months ago

MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of ...

Business Wire - 2 months ago

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company f...

GlobeNewsWire - 3 months ago

MONT-SAINT-GUIBERT, Belgium, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of ...

GlobeNewsWire - 3 months ago

MONT-SAINT-GUIBERT, Belgium, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of ...

GlobeNewsWire - 4 months ago

MONT-SAINT-GUIBERT, Belgium, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development ...

Business Wire - 5 months ago

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of ...

Business Wire - 5 months ago

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company f...

GlobeNewsWire - 5 months ago

MONT-SAINT-GUIBERT, Belgium, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development ...

GlobeNewsWire - 6 months ago

MONT-SAINT-GUIBERT, Belgium, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development o...

Seeking Alpha - 6 months ago

Celyad Oncology's (CYAD) CEO Filippo Petti on First Half 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

MONT-SAINT-GUIBERT, Belgium, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development o...

GlobeNewsWire - 6 months ago

MONT-SAINT-GUIBERT, Belgium, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development o...

Zacks Investment Research - 7 months ago

Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.

GlobeNewsWire - 7 months ago

MONT-SAINT-GUIBERT, Belgium, July 14, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development o...

GlobeNewsWire - 8 months ago

MONT-SAINT-GUIBERT, Belgium, June 10, 2020 (GLOBE NEWSWIRE) -- Celyad SA (Euronext & Nasdaq: CYAD), clinical-stage biotechnology company focused on the discovery and development of chimeric ...

Seeking Alpha - 8 months ago

Celyad's Positive Data And Other News: The Good, Bad And Ugly Of Biopharma

Zacks Investment Research - 8 months ago

The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.

Other stocks mentioned: DXCM, HOLX, NCNA, TDOC
Zacks Investment Research - 9 months ago

Celyad SA (CYAD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 9 months ago

MONT-SAINT-GUIBERT, Belgium, May 06, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of...

GlobeNewsWire - 10 months ago

- Company postpones Extraordinary General Meeting from May 5, 2020 to June 8, 2020 - Company postpones Extraordinary General Meeting from May 5, 2020 to June 8, 2020

Zacks Investment Research - 10 months ago

Top Ranked Momentum Stocks to Buy for April 20th

Other stocks mentioned: ARAV, BCRX, MRSN
Zacks Investment Research - 10 months ago

Celyad SA (CYAD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 11 months ago

Celyad SA (CYAD) CEO Filippo Petti on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

MONT-SAINT-GUIBERT, Belgium, March 02, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development ...

GlobeNewsWire - 1 year ago

MONT-SAINT-GUIBERT, Belgium, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development o...

GlobeNewsWire - 1 year ago

MONT-SAINT-GUIBERT, Belgium, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development o...

GlobeNewsWire - 1 year ago

MONT-SAINT-GUIBERT, Belgium, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development o...

Zacks Investment Research - 1 year ago

Celyad SA (CYAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 1 year ago

MONT-SAINT-GUIBERT, Belgium, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development o...

GlobeNewsWire - 1 year ago

MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development o...

GlobeNewsWire - 1 year ago

MONT-SAINT-GUIBERT, Belgium, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development o...

GlobeNewsWire - 1 year ago

MONT-SAINT-GUIBERT, Belgium, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development ...

GlobeNewsWire - 1 year ago

MONT-SAINT-GUIBERT, Belgium, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development ...

GlobeNewsWire - 1 year ago

MONT-SAINT-GUIBERT, Belgium, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development ...

GlobeNewsWire - 1 year ago

MONT-SAINT-GUIBERT, Belgium, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development ...

GlobeNewsWire - 1 year ago

MONT-SAINT-GUIBERT, Belgium, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development o...

Seeking Alpha - 1 year ago

Celyad SA (CYAD) CEO Filippo Petti on Q2 2019 - Earnings Call Transcript

About CYAD

Celyad Oncology, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of cancer. The company's lead drug product candidates include CYAD-01 and CYAD-02 autologous cell therapies, which are in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. It is also developing CYAD-101, an allogeneic cell therapy that is in Phase I clinical trial for the treatment of metastatic colorectal cancer; and CYAD-103, an allogeneic CAR-T product candidate that is... [Read more...]

Industry
Biotechnology
Founded
2004
CEO
Filippo Petti
Employees
105
Stock Exchange
NASDAQ
Ticker Symbol
CYAD
Full Company Profile

Financial Performance

In 2019, Celyad's revenue was 6,000, a decrease of -99.81% compared to the previous year's 3.12 million. Losses were -28.63 million, -23.50% less than in 2018.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Celyad stock is "Strong Buy." The 12-month stock price forecast is 17.84, which is an increase of 131.09% from the latest price.

Price Target
$17.84
(131.09% upside)
Analyst Consensus: Strong Buy